Kinstellar has advised US-based X-Chem on its acquisition of Hungary's ComInnex.
X-Chem provides pharmaceutical and biotech companies with solutions for screening, hit validation, and lead optimization. The company leverages its DNA-encoded chemical library (DEL) platform to discover novel small molecule leads against therapeutic targets.
ComInnex is a chemistry service organization, supporting early-stage drug discovery through its products and services. The company has over 20 years of experience in offering custom chemistry, chemical library development and synthesis, project management, and customer service.
"As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide," X-Chem CEO Matt Clark commented. "The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help biopharma clients of any size efficiently unlock exponential possibilities in small molecule drug discovery."
"Combining X-Chem, the world leader and pioneer of high-quality DEL technology, and ComInnex, a leader in the most important trends and novel approaches in early-stage drug discovery chemistry, will yield a powerhouse partner for innovative drug discovery solutions," added ComInnex CEO Alex Drijver.
The Kinstellar team was led by Partner Anthony O’Connor and included Managing Associate Agnes Zsofia Szabo, Senior Associate Eszter Takacsi-Nagy, and Junior Associates Bertalan Vanya and Judit Sos.
Editor's Note: After this article was published, CEE Legal Matters learned that Jalsovszky advised the sellers on the transaction. The firm's team included Managing Partner Pal Jalsovszky and Senior Attorneys Peter Gyimesi and Agnes Bejo.
